Phase 4 N=52 Effect On Serum Cholesterol Of Dairy Products With Addition Of Esterified Phytosterols
Dyslipidemias · Hypercholesterolemia
Primary: Serum LDL Cholesterol — 122.2; 113.5 mg/dl
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=57 Effect of Diabetes Mellitus on Cholesterol Metabolism
Type 1 Diabetes Mellitus · Type 2 Diabetes Mellitus · Hypercholesterolemia
Primary: Changes in LDL Cholesterol — -0.83; -1.47; -0.93; -0.32 mmol/L
Phase 3 N=145 High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly
Atherosclerosis · Cardiovascular Disease
Primary: Changes in Plaque Architecture and Composition Directly Measured by Magnetic Resonance Imaging (MRI) in the Aorta and Carotid Arteries — 7; 5 percentage of internal…
Phase 3 N=1,053 Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)
Hypercholesterolemia
Primary: Percent Change From Baseline in LDL-C at Week 6 — -26.7; -12.8 Percent Change — p=<0.001
N/A N=5 Gene Analysis and Treatment Optimization in Chinese Homozygous Familial Hypercholesterolemia
Homozygous Familial Hypercholesterolemia
Primary: Number of LDLR Gene Mutations — 7 gene mutations
N/A N=8 Acute Microvascular Changes With LDL Apheresis
Hyperlipidemia
Primary: Myocardial Perfusion at Rest — 55; 135 IU/s
N/A N=88 Effect of a Treatment With a Nutraceutical Combination on Sub-optimal LDL Cholesterol Levels
Hypercholesterolemia
Primary: Change in Blood LDL Cholesterol Level — -32.48; 2.54 mg/dL — p=<0.0001
Phase 3 N=20 Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study
Metabolic Syndrome X
Primary: Change in Intestinal mRNA Expression Levels of LDL Receptor Between the Two 12-week Interventions — 110531; 95140 #copies/100000 copies housekeeping gene
Phase 2 N=354 Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin
Hypercholesterolemia
Primary: Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 — -2.6; -36.9; -47.6; -56.0 milligram per deciliter (mg/dL) — p=<0.001
Phase 2 N=120 Trial of Antroquinonol in Patients With Hypercholesterolemia and Hyperlipidemia
Hyperlipidemias
Primary: TG Change (mg/dL ) — -9.2; 14.6; -4.2; -1.3 percentage of change
Phase 4 N=25 Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons
Coronary Heart Disease
Primary: Cholesteryl Ester Fractional Clearance Rate
Phase 3 N=58 A Study to Evaluate the Effects of Ezetimibe (MK-0653) on the Postprandial (Following a Meal) Lipoprotein Response in Participants With Primary Hypercholesterolemia (High Cholesterol) (MK-0653-072)(COMPLETED)
Hypercholesterolemia
Primary: Total Cholesterol Concentration of Chylomicron (Sf≥400) Fractions After a Cholesterol-Rich Test Meal — 0.45; 0.50 mg/dL — p=0.241
Phase 3 N=130 A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia
Hyper-low-density Lipoprotein (LDL) Cholesterolemia
Primary: Number of Subjects Experiencing Treatment-Emergent Adverse Events (TEAEs) — 109 Participants
Phase 2 N=36 Safety Study of AEM-28 to Treat Refractory Hypercholesterolemia
Hypercholesterolemia · Hyperlipoproteinemia Type II
Primary: Number of Participants Who Incurred at Least One Treatment Emergent Event — 33; 10 participants
Phase 1 N=49 A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia
Hypercholesterolemia · Dyslipidemias · Hyperlipidemias
Primary: Maximum Observed Plasma Concentration (Cmax) of PF-04950615 — 65810; 15900; 8922; 10470 nanogram per milliliter (ng/mL)
N/A N=1,682 Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1)
Hypercholesterolemia
Primary: Number of Participants Achieving Individual LDL Cholesterol (LDL-C) Target Level — 678 Participants
Phase 3 N=370 A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
Heterozygous Familial Hypercholesterolemia
Primary: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 — -0.3; -54.2 percent change — p=<0.001
Phase 2 N=50 A Multiple Ascending Dose Study of HTD1801 in Adults With Hypercholesterolemia
Hypercholesterolemia
Primary: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) — 8; 10; 8; 11 Participants
Phase 2 N=266 Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia
Hypercholesterolemia
Primary: Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 16 (Intent-to-Treat [ITT] Estimand) — 8.8; -29.7; -44.0; -47.2 Percent…
Phase 3 N=96 A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia
Hyper-low-density Lipoprotein (LDL) Cholesterolemia
Primary: Percent Change in LDL-C From Baseline to Week 12 — -25.25; -3.46 Percent Change — p=0.001
Phase 2 N=619 Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)
Primary Hypercholesterolemia · Mixed Hyperlipidemia
Primary: Change From Baseline in Direct LDL-C at Week 8 — -2.0; -1.5; -4.2; 0.2 Percent change — p=0.06
Phase 4 N=70 Telephone Based Management of Hyperlipidemia
Hyperlipidemia
Primary: LDL Level Change From Baseline — -63.4; -54.6 mg/dl — p=0.391
Phase 3 N=2,139 Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events
Hyperlipidemia
Primary: Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 — 1.0; -54.9 percent change — p=<0.001
Phase 4 N=194 Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol
Hypercholesterolemia
Primary: Percent Change in Plasma Low Density Lipoprotein-cholesterol (LDL-C) From Day 1 (Study Baseline) to Week 8. — 2.9; -3.7; -10.6 percent change from baseline — p=0.1122
Phase 3 N=1,547 MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)
Hypercholesterolemia
Primary: Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase I) — -24.8; -10.1; -13.8 Percentage Change — p=<0.001
Phase 2 N=9 Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
Homozygous Familial Hypercholesterolemia
Primary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline (Week 0) to Week 4 in the Main Study Period — -49.17 Percent Change
Phase 2 N=168 Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study
Hypercholesterolemia, Familial
Primary: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12 — 1.12; -42.70; -55.24 percent change — p=<0.001
Phase 2 N=116 Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
Heterozygous Familial Hypercholesterolemia
Primary: Mean Percent Change in LDL-C From Baseline To Week 12 — -10.6; 8.2 percent change — p=<0.0001
Phase 3 N=146 Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456)
Hypercholesterolemia
Primary: Number of Participants With Adverse Events and Adverse Reactions — 141; 61 Participants
Phase 3 N=579 To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 40 mg (0653-090)
Hypercholesterolemia
Primary: Percent Change From Baseline to Week 6 in Low-Density Lipoprotein (LDL)-C — -27.4; -11.0 Percent Change — p=<0.001